ChristianTRuffMD
Cardiology • Boston, MACardiovascular Disease Genetics
Director of General Cardiology, Brigham and Women's Hospital; Senior Investigator, TIMI Study Group; Associate Professor of Medicine, Harvard Medical School
Dr. Ruff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Brigham & Women's Hospital
Boston, MA 02115Phone+1 617-732-6660
Education & Training
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2006 - 2009- Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2006
Johns Hopkins University School of MedicineClass of 2003
Certifications & Licensure
MA State Medical License 2005 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers.Filipe A Moura, Frederick K Kamanu, Stephen D Wiviott, Robert P Giugliano, Miriam S Udler
Diabetes, Obesity & Metabolism. 2025-03-01 - Long-term visit-to-visit blood pressure variability and risk of cardiovascular and bleeding events: insights from the ENGAGE AF-TIMI 48 trial.Riccardo Proietti, Michael Gerard Palazzolo, Christian T Ruff, Gregory Y H Lip, Robert P Giugliano
Hypertension Research. 2025-02-19 - 1 citationsAbelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.Christian T Ruff, Siddharth M Patel, Robert P Giugliano, David A Morrow, Bruce Hug
The New England Journal of Medicine. 2025-01-23
Journal Articles
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D Wiviott, Marc S Sabatine, Christian T Ruff, Marc P Bonaca, Deepak L Bhatt, Darren K McGuire, The New England Journal of Medicine
- Cardiovascular Safety of Lorcaserin in Overweight or Obese PatientsErin A Bohula, Stephen D Wiviott, Benjamin M Scirica, Darren K McGuire, Marc S Sabatine, Marc P Bonaca, Christian T Ruff, Silvio E Inzucchi, The New England Journal of Medicine
Press Mentions
Study Shows Abelacimab Significantly Reduced Bleeding vs. Standard DOACJanuary 24th, 2025- Fewer Bleeding Events Seen with Abelacimab Than Rivaroxaban in a-fibJanuary 24th, 2025
- Study Shows Anti-Clotting Drug Reduced Bleeding Events in Patients with Atrial FibrillationJanuary 23rd, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
